Indaptus Therapeutics (INDP) stock
Follow INDP's trial news. Members get an alert when Indaptus Therapeutics files news, and see its trials, share raises, and its CEO's filings.
What's next for INDP, and how long its cash lasts
From Indaptus Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words and the arithmetic, not a forecast. Companies often miss their own dates.
Cash runway
About 3 quarters
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first.
Why INDP scores -7
PoorTrending down, 1 of 14 checks firingWhat the Quality Score means
Well below its own recent run. INDP scores -7 today, against a median of 0 over its last 20 recorded sessions.
- −3Long-term trend below a falling 200-day average, down over one year, down over two years
- −2Dilution 202 times as many shares outstanding as a year ago
- Chart checks adds
- Profit subtracts
- Volatility subtracts
- Cash flow subtracts
- News adds
What's next
Expected to report Wed Nov 11, before the open
After its last 3 reports it closed +0.3% on average, higher 2 of 3 times.
What would turn INDP's score around: 8 things, for members
Here is what members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
INDP has 1 of 14 checks firing
One per group is shown here.
How INDP ranks in Biotech
INDP is #271 of 276 by Quality Score. The top three are shown with their scores, and the rest by name.
ABCL10/1420
RGEN8/1420
PBYI11/1419
EXELOpen for its score
ONCOpen for its score
INDP1/14-7
When does INDP report, and what happens after?
Expected to report Wed Nov 11, before the open (in 42 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 13, 2026Before open | Before open | 0.0% | +3.9% | -7.8% |
| May 15, 2026Before open | Before open | +0.8% | -9.1% | -39.4% |
| Nov 12, 2025Before open | Before open | +0.4% | +6.3% | -15.1% |
About Indaptus Therapeutics
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of INDP's score, with the points and the reason
- All 14 checks on INDP and on all 2,953 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on INDP
Straight answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week traits rest on real history. Options flow is not part of the product.
What does it cost?
Nothing for the first 8 days. After that, one plan with everything in it, only if you choose to subscribe: $29 a month, $69 for three months, or $249 a year. Payments go through Stripe, so Breakaway never sees your card.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.